As demonstrated in the VANGUARD Pivotal Phase 3 study
Adverse events with ANDEMBRY
were similar to placebo
* Consists of nasopharyngitis, rhinitis, and upper respiratory infections.
† Consists of abdominal pain and abdominal pain lower.
ANDEMBRY demonstrated favorable long-term safety in the OLE1
Data cut-off: Feb 13, 2023.
‡ TEAEs are categorized as ISR based on medical review of relevant Preferred Terms.
TEAE: treatment-emergent adverse event
§ In the VANGUARD pivotal phase 3 trial.
Get your patients started on ANDEMBRY today!
AE, adverse event; ISR, injection-site reaction; OLE, open-label extension; TEAE, treatment-emergent adverse event.
References: 1. Reshef A, Hsu C, Katelaris CH, et al. Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study. Allergy. 2025;80:545-556. doi:10.1111/all.16351. 2. Craig TJ, Reshef A, Li HH, et al. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet. 2023 Apr 15;401(10384):1266]. Lancet. 2023;401(10382): 1079-1090. doi:10.1016/S0140-6736(23)00350-1.